Adjuvant tyrosine kinase inhibitor therapy improves outcome for children and adolescents with acute lymphoblastic leukaemia who have an ABL-class fusion.
Anthony V MoormanClaire SchwabEmily WintermanJerry HancockAnna CastletonMichelle CumminsBrenda GibsonNick GouldenPamela R KearnsBeki JamesAmy A KirkwoodDonna LancasterMabrouk MadiAndrew McMillanJayashree MotwaniAlice NortonAengus O'MarcaighKatharine PatrickNeha BhatnagarAmrana QureshiDeborah RichardsonSimone StokleyGordon TaylorFrederik W van DelftJohn MoppettChristine J HarrisonSujith SamarasingheAjay VoraPublished in: British journal of haematology (2020)
Patients with an ABL-class fusion have a high risk of relapse on standard chemotherapy but are sensitive to tyrosine kinase inhibitors (TKI). In UKALL2011, we screened patients with post-induction MRD ≥1% and positive patients (12%) received adjuvant TKI. As the intervention started during UKALL2011, not all eligible patients were screened prospectively. Retrospective screening of eligible patients allowed the outcome of equivalent ABL-class patients who did and did not receive a TKI in first remission to be compared. ABL-class patients who received a TKI in first remission had a reduced risk of relapse/refractory disease: 0% vs. 63% at four years (P = 0·009).
Keyphrases
- tyrosine kinase
- end stage renal disease
- chronic myeloid leukemia
- newly diagnosed
- prognostic factors
- randomized controlled trial
- early stage
- advanced non small cell lung cancer
- intensive care unit
- patient reported outcomes
- squamous cell carcinoma
- epidermal growth factor receptor
- systemic lupus erythematosus
- liver failure
- ulcerative colitis
- mechanical ventilation